The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.
The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.
[EN] THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS À BASE DE THIOPYRIMIDINE ET SES UTILISATIONS
申请人:CYTOPIA RES PTY LTD
公开号:WO2008092199A1
公开(公告)日:2008-08-07
[EN] The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases. [FR] L'invention concerne des composés à base de thiopyrimidine, qui sont des inhibiteurs des protéines kinases, y compris des kinases JAK. En particulier, les composés précités sont sélectifs par rapport aux kinases JAK1, JAK2 ou JAK3 et aux combinaisons de ces dernières telles que JAK1 et JAK2. Les inhibiteurs de kinases de l'invention peuvent être utilisés dans le traitement des maladies associées aux kinases, telles que les maladies immunologiques et inflammatoires, y compris les transplantations d'organes; les maladies hyperprolifératives, y compris le cancer et les maladies myéloprolifératives; les maladies virales; les maladies métaboliques; et les maladies vasculaires.